Communication Insurance Coverage and Processing Packaging 
PharmaTech
JUNE 10, 2025
The decision was communicated through a Department of Health and Human Services (HHS) press release. It provides evidence-based recommendations on the use of vaccines for children and adults, informs decisions about insurance coverage, and helps determine eligibility for publicly funded programs such as Vaccines for Children (VFC).
Pharmaceutical Technology
JUNE 6, 2025
The approval process for cell and gene therapy candidates is tricky, however, given their high-cost and oft-debated benefit-risk ratio. RFK Jr did not question their importance, and acknowledged panellists’ calls for faster regulatory processes. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
JUNE 30, 2025
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. We may still continue to send you service-related and other non-promotional communications. This update also suggests we may not see REMS requirements for CD19 and BCMA autologous CAR-T cell therapies in the future,” the research note added.
Pharmaceutical Technology
JUNE 23, 2025
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. We may still continue to send you service-related and other non-promotional communications. In 2024, Otsuka announced the acquisition of US-based Jnana Therapeutics in a deal worth up to $1.1bn. Sign up for our daily news round-up!
Pharmaceutical Technology
JUNE 12, 2025
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. We may still continue to send you service-related and other non-promotional communications. Editorial content is independently produced and follows the highest standards of journalistic integrity. Sign up for our daily news round-up!
Putting Patients First Blog
MARCH 18, 2024
The NHC supports the development and use of processes and tools that enhance beneficiary experience, making interactions with the MPPP smoother and more intuitive for all beneficiaries. It is vital that communication, both for beneficiaries and for health care providers and pharmacists, adhere to these principles.
Putting Patients First Blog
MARCH 18, 2024
The NHC supports the development and use of processes and tools that enhance beneficiary experience, making interactions with the MPPP smoother and more intuitive for all beneficiaries. It is vital that communication, both for beneficiaries and for health care providers and pharmacists, adhere to these principles.
Expert insights. Personalized for you.
85 
Let's personalize your content